PMA device
Optilume BPH Catheter System
Urotronic, Inc. · Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia (QXB, Class III) · First FDA decision Jun 30, 2023, newest Dec 15, 2025Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
5
Naming "Optilume BPH"
MAUDE reports
11
Brand "Optilume BPH", since 2015
PubMed studies
25
Mentioning "Optilume BPH"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Optilume BPH Catheter System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Optilume BPH Catheter SystemPMA supplement
P220029-S003 · Decided Dec 15, 2025 · 28 days after receipt · Normal 180 Day Track No User Fee
Device type: Drug coated prostatic dilation catheter for benign prostatic hyperplasia (QXB) · GI, Urology & Nephrology
- Optilume BPH Catheter SystemPMA supplement
P220029-S002 · Decided Aug 15, 2024 · 86 days after receipt · Normal 180 Day Track
Device type: Drug coated prostatic dilation catheter for benign prostatic hyperplasia (QXB) · GI, Urology & Nephrology
- Optilume BPH Catheter SystemPMA supplement
P220029-S001 · Decided Aug 25, 2023 · 29 days after receipt · Normal 180 Day Track No User Fee
Device type: Drug coated prostatic dilation catheter for benign prostatic hyperplasia (QXB) · GI, Urology & Nephrology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)Local determinationIn effectL38378CGS Administrators, LLCUpdated Mar 25, 2026
- PSA (Addition of ICD-9-CM 600.21, Benign localized hyperplasia of prostate with urinary obstruction as a covered indication)Coding analysisReview closedCAG-00332NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Optilume BPH", any status and sponsor, newest update first.
Dean EltermanAcademic, hospital or other
NCT05567666 · 30 participants · Start Mar 7, 2023 · Primary completion Sep 5, 2025
Device: Optilume Catheter System · For: Benign Prostatic Hyperplasia
Sites: Toronto, Canada
- Optilume™ BPH Catheter System in Men With Symptomatic BPHPivotal-lookingActive, not recruiting
Urotronic Inc.Not on our public-company list
NCT04131907 · 162 participants · Start Feb 5, 2020 · Primary completion Aug 23, 2022
Device: Optilume BPH Catheter System; Optilume Sham Device · For: Benign Prostatic Hyperplasia
Sites: Little Rock, Arkansas; Golden, Colorado; Daytona Beach, Florida · 21 sites in all
Urotronic Inc.Not on our public-company list
NCT06312722 · 92 participants (planned) · Start Feb 7, 2024 · Primary completion Feb 7, 2031
Device: Optilume® BPH Catheter System · For: Benign Prostatic Hyperplasia
Sites: Little Rock, Arkansas; Tampa, Florida; Shreveport, Louisiana · 7 sites in all
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Optilume BPH", and for the whole product code for context.
This brand
11 reports: 2 malfunction, 9 injury, 0 death
Whole product code QXB
12 reports: 2 malfunction, 10 injury, 0 death
Newest reports for this brand
3015228875-0000-00441 · Received Oct 15, 2026 · Event dated Aug 5, 2026
Device type: Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia (QXB)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Hematuria
3015228875-0000-00468 · Received Oct 8, 2026 · Event dated Aug 21, 2026
Device type: Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia (QXB)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Bladder Dysfunction
3015228875-0000-00411 · Received Aug 6, 2026
Device type: Drug Coated Prostatic Dilation Catheter For Benign Prostatic Hyperplasia (QXB)
Device problem as coded: No Apparent Adverse Event
Patient problem as coded: Hematuria
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Optilume BPH"[tiab]. The summary above synthesizes these.
- The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.
Kaplan SA, Moss J, Freedman S, et al. · J Urol · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- How I Do It: Optilume BPH catheter system.
Elterman DS, Gao B, Zorn KC, et al. · Can J Urol · 2023
- The Optilume BPH Catheter System for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Kaur P, Saini S · Transl Androl Urol · 2024Editorial, Comment
- Device profile of Optilume BPH Catheter System for minimally invasive treatment of benign prostatic hyperplasia.
Saffarzadeh M, Derigs M, Ren R, et al. · Expert Rev Med Devices · 2025Review
- Long-term outcomes after treatment with Optilume BPH Four-year results from the EVEREST study.
Kaplan SA, Pichardo M, Rijo E, et al. · Can Urol Assoc J · 2024
- A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men.
Chen DC, Thomson A, Huang S, et al. · Transl Androl Urol · 2024Editorial, Comment
- Optilume, a minimally invasive solution for BPH and urethral stricture: what we know, what we need? an EAU endourology scoping review.
Gauhar V, Yuen SKK, Gadzhiev N, et al. · BMC Urol · 2025Scoping Review
- New Technologies for Treatment of Benign Prostatic Hyperplasia.
Elterman D, Gao B, Lu S, et al. · Urol Clin North Am · 2022Review
- Selecting Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia: A Clinical Consultation Guide.
Chiu PK, Siu BWH, De Nunzio C · Eur Urol Focus · 2025
- Recent Advancements in Prostate Catheters and Stents for Management of Benign Prostatic Hyperplasia.
Lama J, Winograd J, Codelia-Anjum A, et al. · Curr Urol Rep · 2024Review
- Preservation of sexual function with Optilume-a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Copelan O, Moss J, Freedman S, et al. · J Sex Med · 2025Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Impact of minimally invasive surgical therapies on sexual function in benign prostatic hyperplasia: a systematic review.
Akgul B, Aydin A, Cakir OO, et al. · Minerva Urol Nephrol · 2025Systematic Review
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.